EGFR exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas

Схожие документы

• Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
  по: Piotrowska, Zofia, et al.
  Опубликовано: (2015)
• Preclinical Characterization of Mobocertinib Highlights the Putative Therapeutic Window of This Novel EGFR Inhibitor to EGFR Exon 20 Insertion Mutations
  по: Vasconcelos, Pedro E.N.S., et al.
  Опубликовано: (2020)
• EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors
  по: Vasconcelos, Pedro E.N.S., et al.
  Опубликовано: (2020)
• Structural, biochemical and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer
  по: Yasuda, Hiroyuki, et al.
  Опубликовано: (2013)
• Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers
  по: Khandekar, Melin J., et al.
  Опубликовано: (2018)